Medical Devices
All research in Medical Devices — 8 reports.
A good business priced with too little margin of safety today. The Omnipod platform carries a multi-layered moat and the AID category is still gaining penetration; but at $144.94 the owner's yield sits below Treasuries, the ideal buy zone is $110-120, Rating Watch.
A healthcare technology company spun off from 3M, Solventum focuses on medical devices and consumables, dental materials, and hospital software. Demand is structurally necessary, but the moat is only moderate, free cash flow recovery remains unproven, and the company still depends on 3M's supply chain. Report rating Watch: a business worth tracking, with an ideal buy range of $55-65.
Zimmer Biomet is a global orthopedic implant company focused on knee and hip joints, sports medicine, trauma, extremities, and the ROSA robotics and digital platform. Long-term demand is supported by aging and osteoarthritis, and the business generates real cash flow, but its growth quality and moat trail Stryker while the current price of about $82 offers only a discount to neutral value. Rating Watch: the business is worth tracking, but the margin of safety is not yet wide enough, with an ideal buy range of $65 to $75.
A high-quality, cash-generative, net-cash leader in sleep and respiratory health, but at roughly $206 the stock looks more like a good company near fair value than a bargain, with a thin margin of safety; ideal buy range $170-190. Rating Watch: a durable compounder priced for quality, not for safety of margin.
Stryker is a global medical device platform leader with deep moats in orthopaedics, the Mako robotics platform, and neurovascular products. Cash flow continues to strengthen, but at roughly 36.6x PE, valuation is tight and the ideal buy range is $185-230. Research rating Watch: a high-quality compounder that deserves long-term attention, but the current price leaves limited margin of safety.
Medtronic is a global medical-device leader with diversified exposure across cardiovascular, neuroscience, surgical, and diabetes franchises. Its cash flow is resilient, but the current PE of about 22x sits near the upper end of a neutral valuation range, leaving too little margin of safety; adding exposure would be more attractive after a pullback to $60-65. Research rating Hold: a durable compounder, but current pricing limits expected return.
Baxter makes the hospital essentials—IV fluids, infusion systems, pharmacy compounding, surgical hemostats, hospital beds—that care systems depend on every day, but it is still working through the aftermath of the Hillrom acquisition plus 2025 product-safety and execution problems. At roughly $19.18 the stock sits in the gap between my fair-value and optimistic ranges, making it a turnaround stock to watch rather than a core compounding asset. Rating Watch: a stable-demand but middling-economics supplier whose current price gives conservative investors too little margin of safety.
The leader in robot-assisted surgery, with recurring revenue at 84% of the total and a moat built on its ecosystem rather than any single product. But as of 2026-05-22 the stock trades around $439.80 at a trailing P/E of roughly 53.4x, a clear premium to a reasonable intrinsic value of $250-340 with no margin of safety. Rating Watch: a superb business priced for a near-flawless decade.